Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.52 |
| ▸ | MLNR | O43193 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.52 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | NPY1R | P25929 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14681243 | 1.00 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL6856918 | 1.00 | HTR1A (0.52) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL935303 | 0.88 | HTR1A (0.58) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL20007025 | 0.88 | HTR1A (0.58) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL7992903 | 0.88 | HTR1A (0.58) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL16340249 | 0.86 | HTR1A (0.57) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| Hydrochloric Acid SCHEMBL2248981 | 0.86 | HTR1A (0.57) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL6846316 | 0.85 | HTR1A (0.49) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL12846782 | 0.85 | SLC6A2 (0.49) | HTR1AMLNRADRB2ADRB1ADRA2A | |
| SCHEMBL19174388 | 0.85 | HTR1A (0.49) | HTR1AMLNRADRB2ADRB1ADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3974419-A2 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | Zhejiang Ausun Pharmaceutical Co., Ltd. (CN) | 2022-03-30 | — | — | EP | disclosed |
| EP-3405467-B1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INT OPERATIONS LUXEMBOURG SA (LU) | 2021-08-04 | — | — | EP | disclosed |
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. (CN) | 2018-05-24 | — | — | US | disclosed |
| WO-2017125900-A1 | PROCESS FOR THE SYNTHESIS OF INTERMEDIATES OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2017-07-27 | — | — | WO | disclosed |
| EP-2646426-B1 | Process for the preparation of nebivolol | MENARINI INT OPERATIONS LU SA (LU) | 2015-10-07 | — | — | EP | disclosed |
| US-9090922-B2 | Process for the preparation of nebivolol | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2015-07-28 | — | — | US | disclosed |
| US-20130295622-A1 | PROCESS FOR THE PREPARATION OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2013-11-07 | — | — | US | disclosed |
| WO-2013018053-A1 | PROCESS FOR THE PREPARATION OF EPOXIDES AS INTERMEDIATES FOR THE SYNTHESIS OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2013-02-07 | — | — | WO | disclosed |
| WO-2011098474-A1 | PROCESS FOR THE PREPARATION OF NEBIVOLOL | MENARINI INTERNATIONAL OPERATIONS LUXEMBOURG S.A. (LU) | 2011-08-18 | — | — | WO | disclosed |
| WO-2008010022-A2 | A PROCESS FOR PREPARATION OF RACEMIC NEBIVOLOL | CIMEX PHARMA AG (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180141926-A1 | NEBIVOLOL SYNTHESIS METHOD AND INTERMEDIATE COMPOUND THEREOF | CYP4A11, CYP11B2, ADRB1 | HTR1A 1318/4885MLNR 2189/4885ADRB2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.